Drug Profile
Eclitasertib - Denali Therapeutics/Sanofi
Alternative Names: DNL-758; SAR-443122Latest Information Update: 12 Mar 2024
Price :
$50
*
At a glance
- Originator Harvard University
- Developer Denali Therapeutics Inc; Sanofi
- Class 2 ring heterocyclic compounds; Amides; Anti-inflammatories; Antipsoriatics; Antirheumatics; Oxazepines; Pyridines; Skin disorder therapies; Small molecules; Triazoles
- Mechanism of Action RIPK1 protein inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase II Ulcerative colitis
- Discontinued Cutaneous lupus erythematosus; Psoriasis; Rheumatoid arthritis; SARS-CoV-2 acute respiratory disease
Most Recent Events
- 12 Mar 2024 Discontinued - Phase-I for Psoriasis (In volunteers) in USA (unspecified route) (Denali pipeline, February 2024)
- 12 Mar 2024 Discontinued - Phase-I for Rheumatoid arthritis (In volunteers) in USA (unspecified route) (Denali pipeline, February 2024)
- 27 Feb 2024 Efficacy and adverse events data from phase II trial in Cutaneous lupus erythematosus released by Sanofi